The strength cascade is the pricing architecture lens. PharmaDB pulls every form-strength-pack combination from molecule_fdf_prices, normalises to per-mg of active ingredient, and surfaces anomalies in the cascade. Refresh cadence is weekly.
Compare clearance prices across strengths and pack sizes for the same molecule. The empirical strength-cascade map for pricing architecture and arbitrage prevention.
Lenalidomide clears the FDF market in at least seven distinct strength/pack combinations in 2024. The 25mg / 21-cap pack clears at $33.67 median, while the same 25mg in a 30-cap pack clears at $19.87, with a duplicate cluster at $20.86. The 15mg / 21-cap pack sits at $21.99, and 10mg sits in the $15.22 to $20.35 band depending on pack count. The per-mg economics: 25mg / 21-cap is $0.064/mg, 10mg / 30-cap is $0.051/mg. The 10mg pack is structurally cheaper per mg, which means a buyer can arbitrage between strengths if the prescriber substitutes downward. The cascade needs an explicit pricing rule, not a per-pack quote.
Type the molecule INN. The AI agent pulls every form-strength-pack combination with declared clearance shipments.
Per-pack median, per-mg of active ingredient, and the implied price ratio between adjacent strengths. Pricing anomalies (where 2x strength costs less than 2x the half) are flagged.
Citation-anchored brief: the full strength/pack table, the per-mg comparison, and a chip on any anomalies that suggest substitution risk or revenue leakage.
Each combination is its own market clearance band. Aggregating them obscures the cascade; surfacing them individually reveals where the strength uplift is or is not priced.
USD per mg of active ingredient is the comparable unit across strengths. Linear cascade means uniform per-mg; non-linear surfaces as a pricing anomaly the user can act on.
When the 2x-strength pack is below 2x the half-strength pack price per pack, prescribers can substitute upward at the buyer's expense. The brief flags these anomalies so the cascade can be corrected.
FDF aggregates refresh weekly. The cascade reruns on every refresh; the brief carries the exact computation timestamp.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve form-strength-pack combinations · 2024 FDF median · per-pack USD · capsule and tablet.
The strength cascade is the pricing architecture lens. PharmaDB pulls every form-strength-pack combination from molecule_fdf_prices, normalises to per-mg of active ingredient, and surfaces anomalies in the cascade. Refresh cadence is weekly.
The set of all strengths and pack sizes in which a molecule is sold. Pricing across the cascade should be internally consistent: 2x strength priced near 2x the half-strength pack, larger packs priced with the typical bulk discount. Deviation from consistency is a pricing anomaly worth investigating.
The fairest comparison across strengths. A 25mg pack and a 10mg pack are not the same product; the per-mg comparison normalises across both. Non-linear per-mg pricing means the strengths are priced as distinct SKUs, not as a cascade.
Common. Branded equivalent vs generic, parallel-import vs domestic, two regional anchor prices. PharmaDB surfaces both as separate rows. The brief flags the bimodal distribution and notes the spread.
Yes. The form field separates tablets from capsules; cascades are computed within form first. Cross-form comparison is reported separately for the user to interpret (different bioavailability, different manufacturing economics).
When the per-mg price is lower on the lower-strength pack, prescribers can substitute (two 10mg in place of one 25mg) and capture savings at the buyer's cost. PharmaDB flags this anomaly explicitly so the cascade can be repriced.
FDF aggregates refresh weekly. The cascade reruns on every refresh; the catalog row carries the exact timestamp.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.